CD19 and neoplasm: Finally, we focused on the clinical problem of CD19 antigen deficiency after CAR‐T cell treatment and constructed CAR‐ap‐based bispecific circular aptamers that can re‐direct CAR‐T cells to tumor cells and execute the antitumor cytolysis function.